136 related articles for article (PubMed ID: 1712133)
1. Current status of FK 506 in liver transplantation.
Fung JJ; Todo S; Tzakis A; Alessiani M; Abu-Elmagd K; Jain A; Bronster O; Martin M; Gordon R; Starzl TE
Transplant Proc; 1991 Jun; 23(3):1902-5. PubMed ID: 1712133
[No Abstract] [Full Text] [Related]
2. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults.
Todo S; Fung JJ; Tzakis A; Demetris AJ; Jain A; Alessiani M; Takaya S; Day R; Gordon R; Starzl TE
Transplant Proc; 1991 Feb; 23(1 Pt 2):1397-402. PubMed ID: 1703340
[TBL] [Abstract][Full Text] [Related]
3. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.
Fung JJ; Todo S; Jain A; McCauley J; Alessiani M; Scotti C; Starzl TE
Transplant Proc; 1990 Feb; 22(1):6-12. PubMed ID: 1689901
[No Abstract] [Full Text] [Related]
4. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates.
Monden M; Gotoh M; Kanai T; Valdivia LA; Umeshita K; Endoh W; Nakano Y; Kawai M; Ohzato H; Ukei T
Transplant Proc; 1990 Feb; 22(1):66-71. PubMed ID: 1689904
[No Abstract] [Full Text] [Related]
5. Monitoring of anti-rejection therapy by serum bile acids after liver transplantation.
Klar E; Theilmann L; Hoffmann V; Hofmann W; Kraus T; Mehrabi A; Herfarth C
Transplant Proc; 1998 Nov; 30(7):3567-9. PubMed ID: 9838562
[No Abstract] [Full Text] [Related]
6. Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation.
Nishida S; Pinna A; Verzaro R; Levi D; Kato T; Khan F; Nery J; Weppler D; Tzakis A
Transplant Proc; 2001; 33(1-2):1495. PubMed ID: 11267390
[No Abstract] [Full Text] [Related]
7. Trough level-guided mycophenolate mofetil rejection prophylaxis in liver transplantation.
Grasser B; Iberer F; Schaffellner S; Kniepeiss D; Stauber R; Koshsorur G; Rehak P; Tscheliessnigg KH
Transplant Proc; 2001 May; 33(3):2154-6. PubMed ID: 11377484
[No Abstract] [Full Text] [Related]
8. Strategy for chronic rejection in recipient of living-related liver transplantation.
Koyamada N; Ohkohchi N; Doi H; Orii T; Kikuchi H; Chubachi S; Sekiguchi S; Kawagishi N; Haga I; Nakajima N; Satomi S; Oguma S
Transplant Proc; 2000 Nov; 32(7):2134-6. PubMed ID: 11120102
[No Abstract] [Full Text] [Related]
9. Mechanisms of immunosuppressive effects of FK 506 in light of apoptosis of hepatocytes and infiltrating lymphocytes in rat allografted livers.
Moriuchi H; Fujioka H; Gu W; Eguchi S; Kamohara Y; Yamamoto T; Azuma T; Furui J; Koji T; Kanematsu T
Transplant Proc; 2000 Nov; 32(7):2320-1. PubMed ID: 11120182
[No Abstract] [Full Text] [Related]
10. Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage.
Bahra M; Neumann UP; Harren M; Jacob D; Langrehr JM; Berg T; Neuhaus R; Neuhaus P
Transplant Proc; 2002 Nov; 34(7):2934-5. PubMed ID: 12431663
[No Abstract] [Full Text] [Related]
11. Conjugated and delta bilirubin determinations in early liver allograft rejection.
Wu TW; Au JX; Greig PD; Strasberg SM; Ettles M; Abecassis M; Superina RA; Langer B; Blendis L; Phillips MJ
Transplant Proc; 1988 Jun; 20(3 Suppl 3):383-90. PubMed ID: 3291273
[No Abstract] [Full Text] [Related]
12. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients.
Mieles L; Gordon RD; Mintz D; Toussaint RM; Imventarza O; Starzl TE
Transplant Proc; 1991 Feb; 23(1 Pt 2):949-53. PubMed ID: 1703362
[No Abstract] [Full Text] [Related]
13. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group.
Devlin J; Wong P; Williams R; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Bismuth H; Groth C
Transpl Int; 1994; 7 Suppl 1():S64-9. PubMed ID: 11271328
[TBL] [Abstract][Full Text] [Related]
14. Use of FK 506 for treatment of chronic rejection after liver transplantation.
Winkler M; Ringe B; Gerstenkorn C; Rodeck B; Gubernatis G; Wonigeit K; Pichlmayr R
Transplant Proc; 1991 Dec; 23(6):2984-6. PubMed ID: 1721334
[No Abstract] [Full Text] [Related]
15. Diverse effects of FK506 on the apoptosis of hepatocytes and infiltrating lymphocytes in an allografted rat liver.
Moriuchi H; Kamohara Y; Eguchi S; Gu W; Fujioka H; Yamamoto T; Tajima Y; Kanematsu T; Koji T
J Surg Res; 2011 May; 167(1):131-9. PubMed ID: 20018304
[TBL] [Abstract][Full Text] [Related]
16. Maintenance immunosuppression using cyclosporine monotherapy in adult orthotopic liver transplant recipients.
Tchervenkov JI; Tector AJ; Cantarovich M; Tahta SA; Asfar A; Naimi J; Elias N; Barkun J
Transplant Proc; 1996 Aug; 28(4):2247-9. PubMed ID: 8769214
[No Abstract] [Full Text] [Related]
17. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.
Jain AB; Fung JJ; Todo S; Alessiani M; Takaya S; Abu-Elmagd K; Tzakis A; Starzl TE
Transplant Proc; 1991 Feb; 23(1 Pt 2):928-30. PubMed ID: 1703354
[TBL] [Abstract][Full Text] [Related]
18. Can serum liver function tests differentiate rejection from other causes of liver dysfunction after hepatic transplantation?
Sankary HN; Williams JW; Foster PF
Transplant Proc; 1988 Feb; 20(1 Suppl 1):669-70. PubMed ID: 3055469
[No Abstract] [Full Text] [Related]
19. Signs of early rejection of liver transplant in dogs.
Olszewski W; Polański J; Sawicki Z; Machowski Z; Rosnowska M
Pol Med J; 1972; 11(6):1590-5. PubMed ID: 4572846
[No Abstract] [Full Text] [Related]
20. A prospective, multicenter study of once-daily extended-release tacrolimus in de novo liver transplant recipients.
Charco R; Caralt M; Lladó L; Valdivieso A; Fabregat J; Matarranz A; Gonzalez-Pinto I; Pardo F; Fábrega E; Bilbao I
Transplant Proc; 2011 Apr; 43(3):718-23. PubMed ID: 21486582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
